Business Context and Reporting Period
This Form 8-K filing by AcelRx Pharmaceuticals, Inc. (noted as TALPHERA, INC. in metadata) covers the date of August 31, 2012. The report details the entry into a material definitive agreement regarding the potential sale of common stock.
Key Financial Metrics
The filing does not provide specific financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a new sales agreement.
Material Changes
On August 31, 2012, the Company entered into an At Market Issuance Sales Agreement with MLV & Co. LLC. This agreement allows the Company to issue and sell shares of its common stock with an aggregate offering price equal to the lesser of:
- The amount satisfying eligibility requirements for Form S-3.
- The amount available under the Registration Statement on Form S-3 (File No. 333-183237) filed on August 10, 2012.
Sales are subject to the effectiveness of the Registration Statement. The agreement permits sales via "at-the-market" offerings on trading markets or through privately negotiated transactions.
Guidance, Outlook, and Terms
Agreement Terms:
- Duration: The agreement terminates automatically upon the sale of all subject stock or on August 31, 2015, whichever occurs first.
- Termination: Either party may terminate with 10 days' notice; MLV may also terminate in the event of a material adverse change.
- Compensation: The Company will pay MLV a commission of up to 3.0% of gross proceeds.
- Expenses: The Company will reimburse MLV for up to $25,000 in expenses.
Outlook and Risks: The Company makes no assurances that the Registration Statement will become effective or remain effective. The Company is not obligated to sell any stock under the agreement.
Investor Verification Checklist
- Verify the effectiveness status of Registration Statement File No. 333-183237.
- Review the full text of the Sales Agreement (Exhibit 10.1) for specific conditions and limitations.
- Monitor future filings for actual sales volumes and proceeds generated under this agreement.
- Confirm the Company's current eligibility for Form S-3 usage.